Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.
International study illuminates economic burden of late-stage age-related macular degeneration
Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US
Phase 3 COAST trial fails to meet primary endpoints for wet AMD, Opthea reports
The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration
Study examines real-world treat-and-extend outcomes and background factors of macular atrophy
The study demonstrated that the number of injections needed gradually decreased during the follow-up period
Researchers raise awareness of macular pathologies which mimic AMD and GA
Inherited retinal diseases have disease processes distinct from age-related macular degeneration and geographic atrophy, but may present with "phenocopy" clinical signs
Advanced therapies in neovascular AMD and DMO: Experts weigh in
A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden
Cognition Therapeutics announces publication reviewing potential of zervimesine (CT1812) in dry AMD
One in vitro study included in the manuscript was conducted in collaboration with researchers at the University of Southhampton in the United Kingdom